SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2025.
“We continued to execute on our new strategy of focusing on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit in the second quarter. These routine users are increasingly leveraging our OGM systems and software and we believe the recent upgrades to our software and compute platforms will drive further utilization. I’m very proud of our team for driving gross margin above 50% this quarter, which combined with our continued efforts to reduce costs, gives us confidence that our strategy shift is working,” commented Erik Holmlin, PhD, president and CEO of Bionano.
Q2 2025 Financial Results
For the three-month period ended June 30, 2025, as compared to the same period of 2024:
Recent Business Highlights
2025 Outlook
We anticipate the following results for Q3 2025 and the full year:
Webcast Details
Webcast Details
Date: Thursday, August 14, 2025
Time: 4:30 p.m. Eastern Time
Participant Registration: Registration – Click Here
Webcast: https://edge.media-server.com/mmc/p/tnombut6
Participants should register at the link above in advance of the call, and then click the webcast link before the call begins. An archived version of the webcast will be available for replay in the Investors section of the Bionano website.
1 “Non-GAAP gross margin” and “non-GAAP operating expense” are non-GAAP financial measures. Please refer to the section titled “Non-GAAP Financial Measures” below for a description of the non-GAAP financial measures used herein. Reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial tables accompanying this release.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.
For more information, visit www.bionano.com or www.bionanolaboratories.com.
Bionano’s products are for research use only and not for use in diagnostic procedures.
Non-GAAP Financial Measures
To supplement Bionano’s financial results reported in accordance with U.S. generally accepted accounting principles (GAAP), the Company has provided non-GAAP gross margin and non-GAAP operating expense in this press release and the accompanying conference call, each of which is a non-GAAP financial measure. Non-GAAP gross margin excludes from gross margin reported in accordance with GAAP: stock-based compensation and restructuring expenses. Non-GAAP operating expense excludes from operating expense reported in accordance with GAAP: stock-based compensation, amortization of intangibles, changes in fair value of contingent consideration, transaction-related expenses, and loss on disposals. In addition, our reconciliation table provided at the end of this release contains certain additional non-GAAP metrics, including non-GAAP cost of revenue, non-GAAP selling, general and administrative expense, non-GAAP research and development expense, non-GAAP intangible assets and other long-lived assets impairment, and non-GAAP restructuring costs, each with adjustments as presented in the table.
Bionano believes that each of these non-GAAP metrics is useful to investors and analysts as a supplement to its financial information prepared in accordance with GAAP for analyzing the Company’s performance and identifying trends in its business. Bionano uses these non-GAAP metrics internally to facilitate period-to-period comparisons and analysis of its performance in order to understand, manage and evaluate its business, to make operating decisions, and for forecasting and budgeting. Accordingly, Bionano believes presentation of these non-GAAP measure allows for greater transparency with respect to key financial metrics it uses in assessing its own operating performance and making operating decisions.
These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; and the Company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the Company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, each non-GAAP financial measure as used by Bionano in this press release and the accompanying reconciliation table has limits in its usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
For a reconciliation of non-GAAP gross margin to gross margin reported in accordance with GAAP and non-GAAP operating expense to operating expense reported in accordance with GAAP, please refer to the financial tables accompanying this press release.
Forward-Looking Statements of Bionano Genomics
This press release and the accompanying conference call contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our expectations regarding product uptake, revenue, flowcell usage by customers we consider to be routine users of OGM, market development and OGM adoption, including as evidenced through publications highlighting the utility and applications of OGM, our commercial prospects and future financial and operating results, including our full year 2025 and Q3 2025 revenue guidance, cash runway, expected impact from our cost savings initiatives and additional plans to reduce our annualized cost structure, and the timing for such savings; the growth of our installed base of OGM systems; our expectation that our products and innovations will be drivers of future growth; the sales of our flowcell consumables and the other expectations related thereto; our ability to meet our stated goals, including to drive value and penetrate into our target markets; our commercial expectations, including the potential market opportunity for structural variation analysis and OGM; our commercial opportunities related to our OGM systems and our analysis software; continued research, presentations and publications involving OGM, its utility compared to traditional cytogenetics and our technologies; and our ability to drive adoption of OGM and our technology solutions. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the timing and amount of revenue we are able to recognize in a given fiscal period; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a “going concern,” which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the impact of adverse geopolitical and macroeconomic events, such as the ongoing conflicts between Ukraine and Russia and Israel and Gaza and uncertain market conditions, including inflation, tariffs, and supply chain disruptions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; study results that differ or contradict the results mentioned in this press release; the risk that we are not able to complete a strategic transaction that would increase stakeholder value; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as may be required by law.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
Kelly Gura
Gilmartin Group
+1 (212) 229-6163
This email address is being protected from spambots. You need JavaScript enabled to view it.
| BIONANO GENOMICS, INC | |||||||
| Condensed Consolidated Balance Sheet (Unaudited) | |||||||
| (Unaudited) | |||||||
| June 30, 2025 | December 31, 2024 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 3,562,000 | $ | 9,173,000 | |||
| Investments | 12,876,000 | 302,000 | |||||
| Accounts receivable, net | 3,493,000 | 4,752,000 | |||||
| Inventory | 8,633,000 | 11,121,000 | |||||
| Prepaid expenses and other current assets | 3,098,000 | 3,141,000 | |||||
| Restricted investments | 11,000,000 | 11,000,000 | |||||
| Total current assets | 42,662,000 | 39,489,000 | |||||
| Restricted cash | — | 400,000 | |||||
| Property and equipment, net | 17,264,000 | 19,219,000 | |||||
| Operating lease right-of-use asset | 3,772,000 | 1,804,000 | |||||
| Financing lease right-of-use asset | 3,198,000 | 3,299,000 | |||||
| Intangible assets, net | 7,025,000 | 9,705,000 | |||||
| Other long-term assets | 2,089,000 | 2,754,000 | |||||
| Total assets | $ | 76,010,000 | $ | 76,670,000 | |||
| Liabilities and stockholders’ equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 6,244,000 | $ | 6,962,000 | |||
| Accrued expenses | 3,405,000 | 5,641,000 | |||||
| Contract liabilities | 1,165,000 | 1,128,000 | |||||
| Operating lease liability | 1,348,000 | 2,991,000 | |||||
| Finance lease liability | 254,000 | 260,000 | |||||
| Convertible debentures payable (at fair value) | 11,762,000 | 20,362,000 | |||||
| Total current liabilities | 24,178,000 | 37,344,000 | |||||
| Operating lease liability, net of current portion | 2,704,000 | 145,000 | |||||
| Finance lease liability, net of current portion | 3,511,000 | 3,539,000 | |||||
| Long-term contract liabilities | 243,000 | 267,000 | |||||
| Total liabilities | 30,636,000 | 41,295,000 | |||||
| Stockholders’ equity: | |||||||
| Common stock | — | — | |||||
| Preferred Stock | — | — | |||||
| Additional paid-in capital | 748,568,000 | 728,573,000 | |||||
| Accumulated deficit | (703,184,000 | ) | (693,225,000 | ) | |||
| Accumulated other comprehensive income (loss) | (10,000 | ) | 27,000 | ||||
| Total stockholders’ equity | 45,374,000 | 35,375,000 | |||||
| Total liabilities and stockholders’ equity | $ | 76,010,000 | $ | 76,670,000 | |||
| Bionano Genomics, Inc. | |||||||||||||||
| Condensed Consolidated Statement of Operations (Unaudited) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenue: | |||||||||||||||
| Product revenue | $ | 6,310,000 | $ | 6,510,000 | $ | 12,314,000 | $ | 13,338,000 | |||||||
| Service and other revenue | 423,000 | 1,261,000 | 876,000 | 3,202,000 | |||||||||||
| Total revenue | 6,733,000 | 7,771,000 | 13,190,000 | 16,540,000 | |||||||||||
| Cost of revenue: | |||||||||||||||
| Cost of product revenue | 3,150,000 | 4,703,000 | 6,202,000 | 9,607,000 | |||||||||||
| Cost of service and other revenue | 106,000 | 483,000 | 572,000 | 1,525,000 | |||||||||||
| Total cost of revenue | 3,256,000 | 5,186,000 | 6,774,000 | 11,132,000 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 2,931,000 | 6,831,000 | 5,299,000 | 16,608,000 | |||||||||||
| Selling, general and administrative | 8,346,000 | 11,557,000 | 17,379,000 | 30,644,000 | |||||||||||
| Intangible assets and other long-lived assets impairment | — | — | — | 448,000 | |||||||||||
| Restructuring costs | — | 1,215,000 | — | 5,847,000 | |||||||||||
| Total operating expenses | 11,277,000 | 19,603,000 | 22,678,000 | 53,547,000 | |||||||||||
| Loss from operations | (7,800,000 | ) | (17,018,000 | ) | (16,262,000 | ) | (48,139,000 | ) | |||||||
| Other income (expenses): | |||||||||||||||
| Interest income | 277,000 | 457,000 | 566,000 | 1,500,000 | |||||||||||
| Other income (expense) | 676,000 | 363,000 | 5,756,000 | (998,000 | ) | ||||||||||
| Total other income (expense) | 953,000 | 820,000 | 6,322,000 | 502,000 | |||||||||||
| Loss before income taxes | (6,847,000 | ) | (16,198,000 | ) | (9,940,000 | ) | (47,637,000 | ) | |||||||
| Provision for income taxes | (10,000 | ) | (26,000 | ) | (18,000 | ) | (9,000 | ) | |||||||
| Net loss | $ | (6,857,000 | ) | $ | (16,224,000 | ) | $ | (9,958,000 | ) | $ | (47,646,000 | ) | |||
| Bionano Genomics, Inc. | |||||||||||||||
| Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| GAAP gross margin: | |||||||||||||||
| GAAP revenue | $ | 6,733,000 | $ | 7,771,000 | $ | 13,190,000 | $ | 16,540,000 | |||||||
| GAAP cost of revenue | 3,256,000 | 5,186,000 | 6,774,000 | 11,132,000 | |||||||||||
| GAAP gross profit | 3,477,000 | 2,585,000 | 6,416,000 | 5,408,000 | |||||||||||
| GAAP gross margin % | 52 | % | 33 | % | 49 | % | 33 | % | |||||||
| Non-GAAP gross margin: | |||||||||||||||
| GAAP revenue | $ | 6,733,000 | $ | 7,771,000 | $ | 13,190,000 | $ | 16,540,000 | |||||||
| GAAP cost of revenue | 3,256,000 | 5,186,000 | 6,774,000 | 11,132,000 | |||||||||||
| Stock-based compensation expense | (40,000 | ) | (128,000 | ) | (77,000 | ) | (256,000 | ) | |||||||
| COGS restructuring | — | (7,000 | ) | — | (18,000 | ) | |||||||||
| Non-GAAP cost of revenue | 3,216,000 | 5,051,000 | 6,697,000 | 10,858,000 | |||||||||||
| Non-GAAP gross profit | 3,517,000 | 2,720,000 | 6,493,000 | 5,682,000 | |||||||||||
| Non-GAAP gross margin % | 52 | % | 35 | % | 49 | % | 34 | % | |||||||
| GAAP operating expense | |||||||||||||||
| GAAP selling, general and administrative expense | $ | 8,346,000 | $ | 11,557,000 | $ | 17,379,000 | $ | 30,644,000 | |||||||
| Stock-based compensation expense | (880,000 | ) | (2,341,000 | ) | (2,180,000 | ) | (4,057,000 | ) | |||||||
| Intangible asset amortization | (1,340,000 | ) | (1,714,000 | ) | (2,680,000 | ) | (3,506,000 | ) | |||||||
| Change in fair value of contingent consideration | — | 4,476,000 | — | 5,116,000 | |||||||||||
| Transaction related expenses | (63,000 | ) | 91,000 | (126,000 | ) | — | |||||||||
| Loss on disposals | — | — | — | (374,000 | ) | ||||||||||
| Non-GAAP selling, general and administrative expense | 6,063,000 | 12,069,000 | 12,393,000 | 27,823,000 | |||||||||||
| GAAP research and development expense | $ | 2,931,000 | $ | 6,831,000 | $ | 5,299,000 | $ | 16,608,000 | |||||||
| Stock-based compensation expense | (160,000 | ) | (114,000 | ) | (410,000 | ) | (1,285,000 | ) | |||||||
| Non-GAAP research and development expense | 2,771,000 | 6,717,000 | 4,889,000 | 15,323,000 | |||||||||||
| GAAP intangible assets and other long-lived assets impairment | $ | — | $ | — | $ | — | $ | 448,000 | |||||||
| Intangible assets, and other long-lived assets impairment | — | — | — | (448,000 | ) | ||||||||||
| Non-GAAP intangible assets and other long-lived assets impairment | — | — | — | — | |||||||||||
| GAAP restructuring costs | $ | — | $ | 1,215,000 | $ | — | $ | 5,847,000 | |||||||
| Restructuring costs | — | (1,215,000 | ) | — | (5,847,000 | ) | |||||||||
| Non-GAAP restructuring costs | — | — | — | — | |||||||||||
| Total non-GAAP operating expense | $ | 8,834,000 | $ | 18,786,000 | $ | 17,282,000 | $ | 43,146,000 | |||||||
| Last Trade: | US$3.21 |
| Daily Change: | -0.03 -0.93 |
| Daily Volume: | 99,791 |
| Market Cap: | US$10.790M |
August 07, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
